MicroSigX

What MicroSigX does

MicroSigX Biotech Diagnostic Limited is a Hong Kong-based biotech diagnostics company incorporated in December 2024 as a spin-off from The Chinese University of Hong Kong (CUHK) Faculty of Medicine, co-founded by Professor Siew Chien Ng and Professor Francis KL Chan. The company develops and commercializes non-invasive, stool-based microbiome diagnostic tests that apply metagenomic sequencing combined with proprietary machine-learning algorithms to identify disease-specific microbial signatures, serving healthcare providers, hospitals, and research institutions across gastroenterology, neurodevelopmental assessment, and inflammatory bowel disease (IBD) clinical settings.

Its product portfolio includes M3CRC for colorectal cancer risk prediction (94% sensitivity, 90% sensitivity for adenoma recurrence), MSX Metagenie for autism spectrum disorder (ASD) risk prediction (≥95% negative predictive value, FDA Breakthrough Device Designation), and Enterosight for IBD risk prediction (88% sensitivity, 89% specificity). The technology rests on a proprietary databank of over 8,000 analyzed stool samples with more than 1,000 longitudinal metadata points per sample across eight common diseases, processed through deep metagenomic analysis, an in-house ML pipeline, and complementary PCR-based targeted assays. M3CRC is recognized in the 2023 APAGE-APSDE clinical practice guidelines published in BMJ Gut.

MicroSigX generates revenue through one-time diagnostic testing services sold to healthcare providers and research institutions, supplemented by licensing royalties from exclusive CUHK technology and managed-service style government funding under Hong Kong's RAISe+ Scheme. The company executes an enterprise field sales motion with regional offices across mainland China (Beijing, Guangzhou, Shenzhen, Shanghai, Qianhai), the UK, Malaysia, Singapore, and the US, supported by clinical validation partnerships in 14 countries. Pricing is not publicly disclosed, with tests offered through healthcare providers and clinical settings, and the company is preparing NMPA clinical trials for mainland China while targeting FDA approval for MSX Metagenie by 2027.

Name

MicroSigX

Legal name

MicroSigX Biotech Diagnostic Limited

Website

https://microsigx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

MicroSigX is a Hong Kong-based biotech diagnostics spin-off from CUHK that develops and commercializes non-invasive, AI-driven stool microbiome diagnostic tests for colorectal cancer, autism spectrum disorder, and inflammatory bowel disease, sold to hospitals, healthcare providers, and research institutions across 14 countries.

Ownership category

akta.pro rank

Product category

Microbiome Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)

akta.pro secondary industries

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Microbiome diagnostics
• Molecular diagnostics
• Metagenomic sequencing
• Cancer screening
• Autism diagnostics

Headquarters

HQ city

Wan Chai

HQ country

Hong Kong SAR China

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Diagnostic Testing Services: Non-invasive microbiome-based diagnostic tests for colorectal cancer (M3CRC), autism spectrum disorder (MSX Metagenie), and inflammatory bowel disease (Enterosight)
2. Licensing of Proprietary Technology: Exclusive licensing of proprietary microbial biomarkers and algorithms developed through CUHK and MagIC partnership
3. Government Funding: RAISe+ funding from Hong Kong government's Innovation and Technology Commission for developing IBD and ASD diagnostics

Go-to-market motion1 record

Distribution channels4 records

Marketing channels11 records

Core offering

MicroSigX develops and sells non-invasive stool-based microbiome diagnostic tests using proprietary metagenomic sequencing and machine-learning algorithms. Its commercial products include M3CRC for colorectal cancer risk prediction, MSX Metagenie for autism spectrum disorder (ASD) risk prediction, and Enterosight for inflammatory bowel disease (IBD) risk assessment, offered primarily through hospitals, healthcare providers, and research institutions across Asia-Pacific and other global markets.

Product overview

MicroSigX offers a portfolio of non-invasive fecal microbiome-based diagnostic tests developed from proprietary bacterial gene markers and AI-driven metagenomic analysis. The core product lineup includes M3CRC for colorectal cancer risk prediction, MSX Metagenie for autism spectrum disorder (ASD) risk prediction, and Enterosight for inflammatory bowel disease (IBD) risk assessment. These products utilize a unified diagnostic platform that transforms metagenomic sequencing signals into proprietary algorithms, offering stool-based sample collection with dietary recommendations. The company's proprietary microbial biomarkers are non-invasive, biologically relevant, and disease-specific, enabling early detection and monitoring across multiple disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

• M3CRC Non-invasive fecal microbiome test for colorectal cancer risk prediction, detecting CRC with 94% sensitivity and adenoma recurrence with 90% sensitivity. World's only stool microbial prediction test that detects non-progressive adenoma and recurrent adenoma. Recognized in 2023 Joint APAGE-APSDE clinical practice guidelines published in BMJ Gut.
• MSX Metagenie Non-invasive AI-driven microbiome biomarker test for autism spectrum disorder (ASD) risk prediction. First objective test using microbial biomarkers to help exclude ASD with ≥95% negative predictive value. Received FDA Breakthrough Device Designation — the first microbiome-based ASD diagnostic to receive this designation.
• Enterosight Non-invasive fecal test for inflammatory bowel disease (IBD) risk prediction across populations. First non-invasive stool test to predict IBD risk cross-ethnically with 88% sensitivity and 89% specificity. Distinguishes IBD from irritable bowel syndrome (IBS) with high reliability, providing >90% cost savings compared to colonoscopy.
• IBD-SMART MetaGenie Innovative diagnostic solution for inflammatory bowel disease (IBD) based on microbiome biomarkers. Silver Award winner at the 2024 Geneva International Invention Exhibition.
• MetaGenie Platform AI-driven metagenomic analysis platform using proprietary algorithms to transform metagenomic sequencing-derived microbial signals into disease risk prediction algorithms. Silver Award winner at the 2024 Geneva International Invention Exhibition.

Quantifiable outcome

• 94% sensitivity in detecting colorectal cancer, comparable to colonoscopy
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

16 partnerships are on record, tiered major, core and regional.

• CUHK Faculty of Medicine Department of Psychiatry - Advancement Centre for Autism (ADCA)majorStrategic or Co-development Partner · 1 April 2026Founding donor for autism center supporting professional education and autism support ecosystem in Hong Kong
• Centre of Excellence for AutismmajorStrategic or Co-development Partner · 1 December 2025Collaborative network with CUHK Medicine and partners to build autism service ecosystem in Hong Kong
• European Research Centers (France, Germany, Italy, UK)majorStrategic or Co-development Partner · 1 September 2025European collaboration to validate M3CRC across diverse populations, accelerating clinical adoption in the region
• Microbiota I-Center (MagIC)coreStrategic or Co-development Partner · 1 November 2024Joint research laboratory (M-Lab) partnership for connecting upstream scientific discovery with downstream clinical application. MagIC researchers and MicroSigX experts work side by side to accelerate microbiome diagnostic development from biomarker discovery to clinical validation and commercial deployment.
• Chinese University of Hong Kong Faculty of Medicine (CUHK Medicine)coreStrategic or Co-development PartnerAcademic partner providing scientific leadership and clinical insights. Co-founders Prof. Siew Ng and Prof. Francis Chan from CUHK developed the core technology. CUHK provides exclusive licensing of proprietary microbial biomarkers.
• Hong Kong Sanatorium & HospitalcoreStrategic or Co-development PartnerClinical validation and research collaboration for microbiome diagnostic development in Hong Kong
• Beijing Friendship Hospital (Capital Medical University)majorStrategic or Co-development PartnerClinical development and regulatory affairs collaboration in China mainland market
• Changi General Hospital (Singapore)majorStrategic or Co-development PartnerMulti-center research collaboration for M3CRC validation in Singapore market
• Sun Yat-sen University Sixth Affiliated Hospital (China)majorStrategic or Co-development PartnerClinical research partnership for microbiome diagnostics development in China
• National University of MalaysiaregionalStrategic or Co-development PartnerRegional research collaboration in Malaysia for microbiome diagnostic validation
• University of Malaya Medical CentreregionalStrategic or Co-development PartnerHospital network partnership in Malaysia for clinical validation
• Mahidol University (Thailand)regionalStrategic or Co-development PartnerRegional partnership in Thailand for microbiome research collaboration
• King Saud University (Saudi Arabia)regionalStrategic or Co-development PartnerRegional partnership in Middle East for microbiome diagnostic development
• Massachusetts General Hospital Health Professions School (USA)majorStrategic or Co-development PartnerOverseas R&D collaboration center with leading microbiome research institution in USA
• University of Chicago (USA)majorStrategic or Co-development PartnerInternational research collaboration for microbiome diagnostics validation
• InnoHK Initiative (Hong Kong SAR Government)coreStrategic or Co-development PartnerGovernment initiative supporting MagIC research infrastructure that drives MicroSigX technology development

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• ZOE: Consumer health company combining gut microbiome testing with personalized nutrition recommendations using AI/ML. Comparable business model of stool-based sample collection, metagenomic analysis, and ML-driven dietary and health recommendations.
• Viome: Consumer and clinical microbiome diagnostics company offering gut microbiome testing with AI-driven health and disease risk recommendations. Directly comparable business model of stool-based sample collection, metagenomic sequencing, and ML-derived biomarker outputs.
• CosmosID: Microbiome analytics platform offering NGS-based pathogen identification, microbiome characterization, and antimicrobial resistance profiling. Comparable in providing the bioinformatic and sequencing infrastructure underlying microbiome-based diagnostic applications.
• DayTwo: Microbiome-based personalized nutrition and diagnostics company using gut microbiome analysis to predict glycemic response. Comparable in using proprietary ML on metagenomic data to deliver actionable health insights to consumers and providers.
• Genetic Analysis (GA-map): Norwegian microbiome diagnostics company offering the GA-map Dysbiosis Test for gut microbiome profiling. Directly comparable as a clinical microbiome diagnostics company targeting IBD/IBS differentiation and dysbiosis assessment in clinical settings.
• GenieBiome (G-NiiB): Hong Kong-based microbiome precision medicine company sharing the same CEO (Rachel Fan) and academic founders (Prof. Siew Ng, Prof. Francis Chan) from CUHK. Operates in the same microbiome-based diagnostics and therapeutics space with overlapping technology platform and customer base.

Others

• Seres Therapeutics: Clinical-stage microbiome therapeutics company developing microbiome-based drugs for serious diseases. Comparable in leveraging microbiome science for clinical applications, but operates on the therapeutics rather than diagnostics side of the microbiome value chain.

Broad incumbents

• Exact Sciences: Established molecular diagnostics company whose Cologuard test is the dominant non-invasive colorectal cancer screening product in the US. Direct competitor to M3CRC in the non-invasive CRC screening category, with vastly larger commercial scale, reimbursement coverage, and brand recognition.

Emerging players

• Freenome: Multiomics blood-based early-detection company developing tests for colorectal cancer screening. Competes with MicroSigX in the non-invasive CRC screening space, using a different (blood-based) modality but targeting the same clinical and payor customers.
• Bio-Me: Norwegian microbiome-based precision medicine company developing gut microbiome diagnostics for chronic disease stratification. Comparable as a clinical-stage microbiome diagnostics developer using proprietary microbial signatures for disease risk prediction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MicroSigX
• YouTubeyoutube.com/@MicroSigXTest
• Facebookfacebook.com/MicroSigX
• LinkedInlinkedin.com/company/microsigx
• Instagraminstagram.com/microsigxtest

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MicroSigX